Successful treatment of delusions of parasitosis with olanzapine

Archives of Dermatology

Volumn 142, Issue 3, 2006, Pages 352-355

  Meehan, William J ^a   Badreshia, Sonia ^a   Mackley, Christine L ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CEFALEXIN; CLOBETASOL PROPIONATE; NEUROLEPTIC AGENT; OLANZAPINE; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; CASE REPORT; DELUSION; DERMATITIS; ELECTROCARDIOGRAPHY MONITORING; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; MALE; PARASITOSIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DELUSIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARASITIC DISEASES; PIMOZIDE;

EID: 33645098737     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.3.352     Document Type: Article

References (30)

1. Munro A. Monosymptomatic hypochondriacal psychosis. Br J Psychiatry Suppl. 1988;(2):37-40.
2. Koo J, Lee CS. Delusions of parasitosis: a dermatologist's guide to diagnosis and treatment. Am J Clin Dermatol. 2001;2:285-290.
3. Serretti A, De Ronchi D, Lorenzi C, Berardi D. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr Med Chem. 2004;11:343-358.
4. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry. 2003;60:974-977.
5. Ekbom KA. Der prasenile dermatozoenwahn. Acta Psychiatr Neurol Scand. 1938;13:227-259.
6. Lee WR. Matchbox sign. Lancet. 1983;2:457-458.
7. Kim C, Kim J, Lee M, Kang M. Delusional parasitosis as "folie a deux." J Korean Med Sci. 2003;18:462-465.
8. Aw DC, Thong JY, Chan HL. Delusional parasitosis: case series of 8 patients and review of the literature. Ann Acad Med Singapore. 2004;33:89-94.
9. Slaughter JR, Zanol K, Rezvani H, Flax J. Psychogenic parasitosis: a case series and literature review. Psychosomatics. 1998;39:491-500.
10. Zanol K, Slaughter J, Hall R. An approach to the treatment of psychogenic parasitosis. Int J Dermatol. 1998;37:56-63.
11. Lyell A. The Michelson Lecture: delusions of parasitosis. Br J Dermatol. 1983;108:485-499.
12. Reilly TM, Batchelor DH. The presentation and treatment of delusional parasitosis: a dermatological perspective. Int Clin Psychopharmacol. 1986;1:340-353.
13. Morris M. Delusional infestation. Br J Psychiatry Suppl. 1991;(14):83-87.
14. Trabert W. 100 years of delusional parasitosis: meta-analysis of 1,223 case reports. Psychopathology. 1995;28:238-246.
15. Wenning MT, Davy LE, Catalano G, Catalano MC. Atypical antipsychotics in the treatment of delusional parasitosis. Ann Clin Psychiatry. 2003;15:233-239.
16. Elmer KB, George RM, Peterson K. Therapeutic update: use of risperidone for the treatment of monosymptomatic hypochondriacal psychosis. J Am Acad Dermatol. 2000;43:683-686.
17. De Leon OA, Furmaga KM, Canterbury AL, Bailey LG. Risperidone in the treatment of delusions of infestation. Int J Psychiatry Med. 1997;27:403-409.
18. Takahashi T, Ozawa H, Inuzuka S, Harada Y, Hanihara T, Amano N. Sulpiride for treatment of delusion of parasitosis. Psychiatry Clin Neurosci. 2003;57:552-553.
19. Yorston G. Treatment of delusional parasitosis with sertindole. Int J Geriatr Psychiatry. 1997;12:1127-1128.
20. Kumbier E, Kornhuber M. Delusional ectoparasitic infestation in multiple system atrophy [in German]. Nervenarzt. 2002;73:380-383.
21. Freudenmann RW. A case of delusional parasitosis in severe heart failure: olanzapine within the framework of a multimodal therapy [in German]. Nervenarzt. 2003;74:591-595.
22. Weintraub E, Robinson C. A case of monosymptomatic hypochondriacal psychosis treated with olanzapine. Ann Clin Psychiatry. 2000;12:247-249.
23. Fawcett RG. Olanzapine for the treatment of monosymptomatic hypochondriacal psychosis. J Clin Psychiatry. 2002;63:169.
24. Nakaya M. Olanzapine treatment of monosymptomatic hypochondriacal psychosis. Gen Hosp Psychiatry. 2004;26:166-167.
25. Bymaster FP, Rasmussen K, Calligaro DO, et al. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry. 1997;58(suppl 10):28-36.
26. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65(suppl 18):27-35.
27. Ananth J, Parameswaran S, Gunatilake S. Side effects of atypical antipsychotic drugs. Curr Pharm Des. 2004;10:2219-2229.
28. Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome - a case review. Hum Psychopharmacol. 2003;18:301-309.
29. Hiemke C, Dragicevic A, Grunder G, et al. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit. 2004;26:156-160.
30. Guttman C. Olanzapine safe choice for delusions of parasitosis. Dermatology Times. March 2001:21.